A collection of 68 research compounds deprioritised by their developers are now available to UK researchers as a result of a compound-sharing project coordinated by the Medical Research Council.
UK scientists can apply for MRC responsive-mode funding to use any of the compounds in their research to develop more effective treatments for a range of conditions, the MRC said in a statement on 8 December.
The collection includes both clinical compounds already tested in humans and pre-clinical compounds, including candidates developed for a range of diseases including cancer, ADHD, narcolepsy and diabetes. The compounds have all undergone some industry development, but have stalled in early testing often because they were not effective enough against the disease in question.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.